Let-7c down-regulation in Helicobacter pylori-related gastric carcinogenesis

Oncotarget

Volumn 7, Issue 4, 2016, Pages 4915-4924

  Fassan, Matteo ^a   Saraggi, Deborah ^a   Balsamo, Laura ^a   Cascione, Luciano ^b   Castoro, Carlo ^c   Coati, Irene ^a   De Bernard, Marina ^a   Farinati, Fabio ^a   Guzzardo, Vincenza ^a   Valeri, Nicola ^d   Zambon, Carlo Federico ^a   Rugge, Massimo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Gastric adenocarcinoma; Helicobacter pylori; MicroRNA; Preneoplastic lesions

Indexed keywords

ANTIINFECTIVE AGENT; MICRORNA; MICRORNA LET 7C; UNCLASSIFIED DRUG; MESSENGER RNA; MIRNLET7 MICRORNA, HUMAN;

ADULT; ARTICLE; ATROPHIC GASTRITIS; ATROPHIC METAPLASTIC GASTRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE GASTRITIS; CANCER SURGERY; CONTROLLED STUDY; DISEASE SEVERITY; DNA MODIFICATION; DOWN REGULATION; DYSPEPSIA; ENVIRONMENTAL FACTOR; ERADICATION THERAPY; FEMALE; GASTRIC MUCOSA; GASTRITIS; GENE CONTROL; GENE EXPRESSION PROFILING; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METAPLASIA; PHENOTYPE; SEROLOGY; STOMACH BIOPSY; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH SURGERY; STOMACH TUMOR; TUMOR INVASION; CANCER STAGING; CARCINOGENESIS; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; HELICOBACTER PYLORI; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY;

CARCINOGENESIS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 84957990317     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6642     Document Type: Article

References (45)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5-29.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87-108.
3. Rugge M, Fassan M, Graham DY. Clinical guidelines: Secondary prevention of gastric cancer. Nat Rev Gastroenterol Hepatol. 2012; 9: 128-129.
4. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015; 148: 719-31.e3.
5. Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer.Journal international du cancer. 2015; 136: 487-490.
6. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. NEJM. 2001; 345: 784-789.
7. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P, faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015; 64:1353-1367.
8. Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013; 42: 211-217.
9. Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol. 2013; 27: 205-223.
10. Genta RM, Rugge M. Atrophic Gastritis in the Arctic. Clin Gastroenterol Hepatol. 2015; 10: 1601-1603.
11. Rugge M, Pennelli G, Pilozzi E, Fassan M, Ingravallo G, Russo VM, Di Mario F, Gruppo Italiano Patologi Apparato Digerente (GIPAD), Societa Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP). Gastritis: the histology report. Dig Liver Dis. 2011; 43 Suppl 4: S373-84.
12. Nordenstedt H, Graham DY, Kramer JR, Rugge M, Verstovsek G, Fitzgerald S, Alsarraj A, Shaib Y, Velez ME, Abraham N, Anand B, Cole R, El-Serag HB. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol. 2013; 108: 65-71.
13. Rugge M, Fassan M, Pizzi M, Zorzetto V, Maddalo G, Realdon S, De Bernard M, Betterle C, Cappellesso R, Pennelli G, de Boni M, Farinati F. Autoimmune gastritis: histology phenotype and OLGA staging. Aliment Pharmacol Ther. 2012; 35: 1460-1466.
14. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513: 202-209.
15. Fassan M, Baffa R, Kiss A. Advanced precancerous lesions within the GI tract: the molecular background. Best Pract Res Clin Gastroenterol. 2013; 27: 159-169.
16. Bornschein J, Leja M, Kupcinskas J, Link A, Weaver J, Rugge M, Malfertheiner P. Molecular diagnostics in gastric cancer. Front Biosci (Landmark edition). 2014; 19: 312-338.
17. D'Angelo E, Vicentini C, Agostini M, Kiss A, Baffa R, Scarpa A, Fassan M. MicroRNAs as tools and effectors for patient treatment in gastrointestinal carcinogenesis. Curr Drug Targets. 2015; 16: 383-392.
18. Fassan M, Croce CM, Rugge M. miRNAs in precancerous lesions of the gastrointestinal tract. World J Gastroenterol. 2011; 17: 5231-5239.
19. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, Cavazzini L, Volinia S, Alder H, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008; 13: 272-286.
20. Matsushima K, Isomoto H, Inoue N, Nakayama T, Hayashi T, Nakayama M, Nakao K, Hirayama T, Kohno S. MicroRNA signatures in Helicobacter pylori-infected gastric mucosa. Int J Cancer. 2011; 128: 361-370.
21. Hayashi Y, Tsujii M, Wang J, Kondo J, Akasaka T, Jin Y, Li W, Nakamura T, Nishida T, Iijima H, Tsuji S, Kawano S, Hayashi N, et al. CagA mediates epigenetic regulation to attenuate let-7 expression in Helicobacter pylori-related carcinogenesis. Gut. 2013; 62: 1536-1546.
22. Liu WJ, Xu Q, Sun LP, Dong QG, He CY, Yuan Y. Expression of serum let-7c, let-7i, and let-7f microRNA with its target gene, pepsinogen C, in gastric cancer and precancerous disease. Tumour Biol. 2015; 36: 3337-3343.
23. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res. 2008; 14: 2334-2340.
24. Fassan M, Volinia S, Palatini J, Pizzi M, Baffa R, De Bernard M, Battaglia G, Parente P, Croce CM, Zaninotto G, Ancona E, Rugge M. MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer. 2011; 129: 1661-1670.
25. Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis-pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013; 10: 529-541.
26. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000; 403: 901-906.
27. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014; 9: 287-314.
28. Fassan M, Baffa R, Kiss A, Zaninotto G, Rugge M. MicroRNA dysregulation in esophageal neoplasia: the biological rationale for novel therapeutic options. Curr Pharm Des. 2013; 19: 1236-1241.
29. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101: 2999-3004.
30. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol. 2008; 18: 505-516.
31. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004; 64: 3753-3756.
32. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell. 2005; 120: 635-647.
33. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9: 189-198.
34. Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, Winslow MM, Downward J. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature. 2014; 505: 212-217.
35. Zhu X, Wu L, Yao J, Jiang H, Wang Q, Yang Z, Wu F. MicroRNA let-7c Inhibits Cell Proliferation and Induces Cell Cycle Arrest by Targeting CDC25A in Human Hepatocellular Carcinoma. PloS one. 2015; 10: e0124266.
36. Nomura S, Baxter T, Yamaguchi H, Leys C, Vartapetian AB, Fox JG, Lee JR, Wang TC, Goldenring JR. Spasmolytic polypeptide expressing metaplasia to preneoplasia in H. felis-infected mice. Gastroenterology. 2004; 127: 582-594.
37. Weis VG, Sousa JF, LaFleur BJ, Nam KT, Weis JA, Finke PE, Ameen NA, Fox JG, Goldenring JR. Heterogeneity in mouse spasmolytic polypeptide-expressing metaplasia lineages identifies markers of metaplastic progression. Gut. 2013; 62: 1270-1279.
38. Petersen CP, Weis VG, Nam KT, Sousa JF, Fingleton B, Goldenring JR. Macrophages promote progression of spasmolytic polypeptide-expressing metaplasia after acute loss of parietal cells. Gastroenterology. 2014; 146: 1727-38.e8.
39. Lee J, Ha S, Jung CK, Lee HH. High-mobility-group A2 overexpression provokes a poor prognosis of gastric cancer through the epithelial-mesenchymal transition. Int J Oncol. 2015; 46: 2431-2438.
40. Rugge M, Capelle LG, Fassan M. Individual risk stratification of gastric cancer: evolving concepts and their impact on clinical practice. Best Pract Res Clin Gastroenterol. 2014; 28: 1043-1053.
41. Rugge M, Correa P, Dixon MF, Fiocca R, Hattori T, Lechago J, Leandro G, Price AB, Sipponen P, Solcia E, Watanabe H, Genta RM. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharm Ther. 2002; 16: 1249-1259.
42. Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K, Riddell RH, Sipponen P, Watanabe H. Gastric dysplasia: the Padova international classification. Am J Surg Pathol. 2000; 24: 167-176.
43. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol. 2005; 36: 228-233.
44. Fassan M, Pizzi M, Realdon S, Balistreri M, Guzzardo V, Zagonel V, Castoro C, Mastracci L, Farinati F, Nitti D, Zaninotto G, Rugge M. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. Hum Pathol. 2013; 44: 1804-1810.
45. Perilli L, Vicentini C, Agostini M, Pizzini S, Pizzi M, D'Angelo E, Bortoluzzi S, Mandruzzato S, Mammano E, Rugge M, Nitti D, Scarpa A, Fassan M, et al. Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. Oncotarget. 2014; 5: 6611-6619. doi: 10.18632/oncotarget.2245.